Clincosm LogoSign in Get a demo

ESGiTX: Prospective Pilot Study for the Evaluation of Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Liver Transplant Candidates

Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Other)
Overall Status
Recruiting
CT.gov ID
NCT05760235
Collaborator
(none)
24
Enrollment
1
Location
1
Arm
24.6
Anticipated Duration (Months)
1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this pilot prospective interventional study is to evaluate the efficacy of endoscopic sleeve gastroplasty (ESG) in allowing obese subjects with the need of liver transplantation to reduce their BMI in order to enter the waiting list (BMI (≥35 kg/m2). The main question[s] it aims to answer are:

  • Is the procedure effective in reducing BMI to the target level in 12 months?

  • Which is the effect on weight loss, quality of life and obesity-related comorbidities?

Participants will undergo ESG as per standard clinical practice and followed up to 12 months before transplantation and for 12 months after transplantation

Condition or Disease Intervention/Treatment Phase
  • Procedure: Endoscopic sleeve gastroplasty (ESG)
 N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Prospective Pilot Study for the Evaluation of Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Liver Transplant Candidates
Actual Study Start Date :
Oct 13, 2022
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Nov 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Liver transplant obese candidates

Subjects with an indication to liver transplantation that are not listed because of a high BMI according to the policy of the transplant Centre (cut-off 35 kg/m2)

Procedure: Endoscopic sleeve gastroplasty (ESG)
ESG will be performed under general anaesthesia with orotracheal intubation. The Endomina® suturing system (EndoTools Therapeutics S.A., Gosselies, Belgium) mounted on a single channel endoscope will be used. This system allows to obtain full thickness gastric sutures through the gastric wall of the gastric body, leaving the antrum and the gastric fundus free15. The procedure will be performed with the patient in supine position. Carbon dioxide will be blown to stretch the gastric lumen. An initial endoscopic evaluation will be performed immediately to confirm the absence of any contraindication to ESG before suturing. The ESG starts with the reduction of the gastric body, suturing from distal to proximal and starting from the notch of the angulus and ending at the level of the fundus. 4-8 full thickness stitches will be placed, with 2 passes per stitch.

Outcome Measures

Primary Outcome Measures

  1. Transplant list inclusion [12 months]

    number of patients who achieve a BMI < 35 kg/m² within 12 months post-ESG, allowing them to be included in the transplant list

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Adult patients (i.e., age between 18 and 70 years).

  • BMI ≥ 35 kg/m²;

  • Subjects with an indication to liver transplantation that are not listed because of a high BMI according to the policy of the transplant Centre (cut-off 35 kg/m2);

  • Signed informed consent.

Exclusion Criteria:

  • Clinically significant portal hypertension at upper endoscopy: F3 or F1/F2 with red signs oesophageal varices, gastric varices or severe hypertensive gastropathy;

  • Upper gastro-intestinal bleeding (gastric or esophageal) in the previous six months;

  • CHILD C class;

  • Clinically or ultrasound-detected ascites in the 15 days before the procedure. Only mild ascitic effusion in the pelvis will be accepted;

  • Spontaneous bacterial peritonitis in the previous 6 months;

  • Hepatocellular carcinoma with extra hepatic spread;

  • Previous stomach, oesophagus or duodenum surgery;

  • Technical non-feasibility in the opinion of the endoscopist;

  • Clinical signs of active infection;

  • Unstable cardiac disease or chronic heart failure;

  • Platelet count less than 70.000;

  • Internationa Normalized Ratio ≥ 1,5;

  • Concomitant unstoppable anticoagulant or anti platelet therapy, except for low dose aspirin (≤ 100 mg);

  • Acute liver failure;

  • Easy to bleed during diagnostic endoscopy;

  • Active drugs or alcohol abuse;

  • Pregnancy, lactation (desire to become pregnant during study duration);

  • Enrolment in other clinical studies;

  • Contraindication to general anaesthesia;

  • Contraindication to endoscopic procedure;

  • Other conditions to exclude the subject in investigators opinion;

  • Refusal to sign informed consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fondazione Policlinico Gemelli IRCCS Roma Lazio Italy 00168

Sponsors and Collaborators

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ClinicalTrials.gov Identifier:
NCT05760235
Other Study ID Numbers:
  • 4903
First Posted:
Mar 8, 2023
Last Update Posted:
Mar 8, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Obesity

Study Results

No Results Posted as of Mar 8, 2023